Eikon Therapeutics Inc

Research Eikon Therapeutics Inc (EIKN) on Bullrun: market cap USD 689.73M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerEIKN
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 689.73M
• Financial periodQ1 2026
• Net income-USD 82.96M
• Free cash flow-USD 90.06M

Valuation Snapshot

latest market cap is USD 689.73M.

About Eikon Therapeutics Inc

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant;

Frequently asked questions

What is Eikon Therapeutics Inc's market cap?

Eikon Therapeutics Inc's market capitalization is USD 689.73M.

What does Eikon Therapeutics Inc do?

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.